Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

Dick de Zeeuw(University of Groningen), Rajiv Agarwal(Indiana University School of Medicine), Michael Amdahl(Abbott (United Kingdom)), Paul Audhya(Abbott (United Kingdom)), Daniel W. Coyne(Washington University in St. Louis), Τushar Garimella(Abbott (United Kingdom)), Hans‐Henrik Parving(Aarhus University), Yili Pritchett(Abbott (United Kingdom)), Giuseppe Remuzzi(Mario Negri Institute for Pharmacological Research), Eberhard Ritz(Heidelberg University), Dennis L. Andress(Abbott (United Kingdom))

The Lancet

November 1, 2010

10.1016/s0140-6736(10)61032-x

Cited by 690

Abstract

Related Papers

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

Johannes F.E. Mann, Roland E. Schmieder, Matthew McQueen et al.|The Lancet|2008|1.6k

Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease

Adeera Levin, George L. Bakris, Mark E. Molitch et al.|Kidney International|2006|1.5k

Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy

Ming Teng, Myles Wolf, Edmund G. Lowrie et al.|New England Journal of Medicine|2003|924

Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients

Kamyar Kalantar‐Zadeh, Noriko Kuwae, Deborah L. Regidor et al.|Kidney International|2006|904

Vitamin D: a negative endocrine regulator of the renin–angiotensin system and blood pressure

Yan Chun Li, Guilin Qiao, Milan R. Uskoković et al.|The Journal of Steroid Biochemistry and Molecular Biology|2004|616